StockNews.com started coverage on shares of CEL-SCI (NYSE:CVM – Free Report) in a research report released on Wednesday morning. The firm issued a sell rating on the stock.
CEL-SCI Price Performance
NYSE:CVM opened at $0.43 on Wednesday. The firm has a market cap of $31.46 million, a price-to-earnings ratio of -0.73 and a beta of 0.65. The firm’s fifty day moving average is $0.62 and its two-hundred day moving average is $0.95. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.18 and a current ratio of 0.64. CEL-SCI has a one year low of $0.36 and a one year high of $3.08.
Hedge Funds Weigh In On CEL-SCI
Institutional investors have recently made changes to their positions in the company. Calton & Associates Inc. acquired a new position in shares of CEL-SCI during the 3rd quarter worth approximately $50,000. Black Diamond Financial LLC raised its position in CEL-SCI by 35.8% during the second quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock worth $84,000 after acquiring an additional 19,000 shares during the period. Plotkin Financial Advisors LLC purchased a new position in CEL-SCI during the third quarter valued at $98,000. Thoroughbred Financial Services LLC grew its position in shares of CEL-SCI by 140.9% in the second quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock valued at $158,000 after purchasing an additional 80,001 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of CEL-SCI by 29.9% during the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after purchasing an additional 40,000 shares in the last quarter. 12.08% of the stock is owned by hedge funds and other institutional investors.
About CEL-SCI
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.
Read More
- Five stocks we like better than CEL-SCI
- Upcoming IPO Stock Lockup Period, Explained
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What Do S&P 500 Stocks Tell Investors About the Market?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- What is the Nasdaq? Complete Overview with History
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.
